ADHD Medications: Is More Always Better?

A major new study published in The Lancet Psychiatry has provided important insights into one of the most common questions in ADHD treatment: how much medication is enough?

In their systematic review and dose–effect network meta-analysis, Nourredine and colleagues analysed data from 113 double-blind randomised controlled trials involving more than 25,000 participants with attention-deficit/hyperactivity disorder (ADHD). The study examined the relationship between medication dose, effectiveness, and tolerability across a range of stimulant and non-stimulant treatments in both children and adults.

The findings challenge the assumption that increasing medication doses will always result in better symptom control.

For children and adolescents, methylphenidate demonstrated increasing effectiveness up to approximately 45 mg daily, beyond which additional benefits appeared limited. Amphetamines showed a similar pattern, with efficacy increasing up to around 25 mg daily before reaching a plateau. Guanfacine also demonstrated a dose-related improvement, with benefits levelling off at approximately 4 mg daily.

In adults, amphetamines continued to show increasing efficacy up to around 50 mg daily, after which further dose increases provided little additional benefit. The picture for methylphenidate was less clear in adults, with some evidence suggesting continued improvement at higher doses, although the available data were less robust.

Importantly, the study did not focus solely on effectiveness. The authors also examined treatment discontinuation due to adverse effects, providing valuable information about the balance between benefits and harms. Higher doses of amphetamines were associated with increased rates of discontinuation in both children and adults. Similarly, adults receiving higher doses of methylphenidate were more likely to stop treatment because of side effects.

These findings have significant implications for clinical practice. ADHD treatment often requires careful dose titration, yet clinicians can face two opposing challenges. The first is therapeutic inertia, where medication doses are not increased despite a partial response, potentially leaving symptoms inadequately treated. The second is excessive dose escalation, where doses continue to rise despite diminishing returns and increasing adverse effects.

The study suggests that many patients may achieve optimal benefit within a relatively predictable dose range. Beyond this point, clinicians and patients should carefully consider whether further increases are likely to improve outcomes or simply increase the risk of side effects.

The findings are also relevant to shared decision-making. Patients and families frequently ask whether increasing a dose might produce better symptom control. This analysis provides evidence-based guidance that can help inform those discussions and set realistic expectations.

As with all meta-analyses, some limitations exist. Data were sparse at the highest doses for several medications, meaning estimates become less certain at the extremes of dosing. In addition, individual responses to ADHD medication can vary considerably, and treatment decisions should always be personalised.

Nevertheless, this study represents one of the most comprehensive evaluations of ADHD medication dosing to date. Its message is clear: effective treatment is not simply about finding the highest tolerated dose. Instead, the goal should be to identify the dose that delivers the greatest clinical benefit while minimising adverse effects. For many patients, more is not necessarily better.